• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
ARCT

ARCT

Arcturus Therapeutics Holdings Inc.

NASDAQHealthcareBiotechnologyUS

USD7.60

-0.05 (-0.65%)

Rating:C

Company Profile

CEO

Joseph E. Payne

IPO Date

2013-05-22

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$7.62

Prev. Close

$7.65

Day Low

$7.39

Day High

$7.64

52W Low

$5.85

52W High

$24.17

Market Cap

$0.22B

Volume

0.47M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

44.7%

Avg Negative

3.5%

Avg Neutral

51.5%

News Feed

ARCT Stock Price Increases Over 35% Pre-Market: Why It Happened

Pulse2·8/10/2021·↑ positive

Arcturus Therapeutics Holdings Inc. (ARCT) CEO Joseph Payne on Q2 2021 Results - Earnings Call Transcript

Seeking Alpha·8/10/2021·↓ negative

Arcturus Therapeutics (ARCT) Reports Q2 Loss, Lags Revenue Estimates

Zacks Investment Research·8/9/2021·↑ positive

Why Arcturus Therapeutics Stock Is Soaring Today

The Motley Fool·8/3/2021·↑ positive

ARCT Stock Price Increases Over 6% Pre-Market: Why It Happened

Pulse2·8/3/2021·↑ positive

Earnings Preview: Arcturus Therapeutics (ARCT) Q2 Earnings Expected to Decline

Zacks Investment Research·8/2/2021·↑ positive

Arcturus Therapeutics Stock Jumps On Establishment Of COVID-19 Vaccine Plant In Vietnam

Benzinga·8/2/2021·↑ positive

Arcturus Therapeutics Collaborates with Vingroup to Establish Manufacturing Facility in Vietnam for Arcturus' Investigational mRNA Vaccines for COVID-19

Business Wire·8/2/2021·↑ positive

Arcturus Therapeutics Holdings' (ARCT) CEO Joseph Payne on Q1 2021 Results - Earnings Call Transcript

Seeking Alpha·5/10/2021·↓ negative

Arcturus Therapeutics (ARCT) Reports Q1 Loss, Lags Revenue Estimates

Zacks Investment Research·5/10/2021·↑ positive